Phico Therapeutics, a biotechnology company developing a novel platform technology for a new generation of antibiotics aimed at overcoming antibacterial resistance, has been awarded a 2.25M Translation Award by the Wellcome Trust to develop its SASPject PT4 antibiotic, aimed at Escherichia coli and Klebsiella pneumonia e . SASPject 's PT4 is targeted at E. coli and K. pneumoniae , including multi-drug resistant strains.